China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight ...
Tirzepatide, known in the U.S. under the brand names Mounjaro for diabetes and Zepbound for weight loss, will now be used in China to treat adults with type 2 diabetes.
Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100 billion globally by decade's end. Both companies' obesity treatments belong to ...
Eli Lilly (NYSE:LLY) has secured China approval for its blockbuster drug tirzepatide for use in treating diabetes. Tirzepatide, a novel dual agonist at both the GLP-1 and the glucose-dependent ...
, opens new tab said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk (NOVOb.CO ...
China alone, the market is expected to grow to 14.9 billion yuan ($2 billion) by 2030. The approval is potentially paving the way for off-label use of Tirzepatide for weight loss, similar to Wegvoy.
SHANGHAI (Reuters) - Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in ...
Benzinga - by Vandana Singh, Benzinga Editor. On Tuesday, Eli Lilly And Company (NYSE:LLY) announced that Chinese regulators have approved its diabetes drug tirzepatide. This approval sets the stage ...